BRPI1006514A2 - antagonista do gm-csf - Google Patents
antagonista do gm-csfInfo
- Publication number
- BRPI1006514A2 BRPI1006514A2 BRPI1006514A BRPI1006514A BRPI1006514A2 BR PI1006514 A2 BRPI1006514 A2 BR PI1006514A2 BR PI1006514 A BRPI1006514 A BR PI1006514A BR PI1006514 A BRPI1006514 A BR PI1006514A BR PI1006514 A2 BRPI1006514 A2 BR PI1006514A2
- Authority
- BR
- Brazil
- Prior art keywords
- csf antagonist
- csf
- antagonist
- Prior art date
Links
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 title 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17547109P | 2009-05-05 | 2009-05-05 | |
| PCT/EP2010/056012 WO2010128035A1 (en) | 2009-05-05 | 2010-05-04 | Treatment for multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1006514A2 true BRPI1006514A2 (pt) | 2019-01-08 |
Family
ID=42541538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1006514A BRPI1006514A2 (pt) | 2009-05-05 | 2010-05-04 | antagonista do gm-csf |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20120116059A1 (pt) |
| EP (1) | EP2427495A1 (pt) |
| JP (1) | JP2012530047A (pt) |
| KR (2) | KR20120011883A (pt) |
| CN (1) | CN102439039A (pt) |
| AU (1) | AU2010244525B2 (pt) |
| BR (1) | BRPI1006514A2 (pt) |
| CA (1) | CA2760755A1 (pt) |
| RU (1) | RU2539034C2 (pt) |
| WO (1) | WO2010128035A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104995210A (zh) * | 2012-09-20 | 2015-10-21 | 莫弗系统股份公司 | 类风湿关节炎的治疗 |
| KR20210021153A (ko) * | 2012-09-20 | 2021-02-24 | 모르포시스 아게 | 류마티스 관절염에 대한 치료 |
| WO2014068029A1 (en) * | 2012-10-31 | 2014-05-08 | Takeda Gmbh | Lyophilized formulation comprising gm-csf neutralizing compound |
| AR093297A1 (es) | 2012-10-31 | 2015-05-27 | Amgen Res Munich Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| KR102204476B1 (ko) * | 2013-08-14 | 2021-01-19 | 주식회사 젬백스앤카엘 | 다발성 경화증 치료 및 예방용 조성물 |
| EP3039039B1 (en) | 2013-08-30 | 2021-03-10 | Takeda GmbH | Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1874819T1 (sl) * | 2005-04-18 | 2015-09-30 | Amgen Research (Munich) Gmbh | Protitelesni nevtralizatorji humanega faktorja stimulacije kolonij granulocitov makrofagov |
| CA2608498C (en) * | 2005-05-18 | 2017-04-04 | Morphosys Ag | Anti-gm-csf antibodies and uses therefor |
| DK1999152T3 (da) * | 2006-03-27 | 2013-01-14 | Medimmune Ltd | Bindende element til gm-csf-receptor |
| MX2009005398A (es) * | 2006-11-21 | 2009-08-20 | Kalobios Pharmaceuticals Inc | Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf. |
| RU2353367C2 (ru) * | 2007-05-17 | 2009-04-27 | Государственное образовательное учреждение высшего профессионального образования "Российский университет дружбы народов" (РУДН) | Способ лечения клинических проявлений рассеянного склероза |
| TW200918553A (en) * | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
-
2010
- 2010-05-04 BR BRPI1006514A patent/BRPI1006514A2/pt not_active IP Right Cessation
- 2010-05-04 CN CN201080019701XA patent/CN102439039A/zh active Pending
- 2010-05-04 AU AU2010244525A patent/AU2010244525B2/en not_active Ceased
- 2010-05-04 WO PCT/EP2010/056012 patent/WO2010128035A1/en not_active Ceased
- 2010-05-04 KR KR1020117029055A patent/KR20120011883A/ko not_active Ceased
- 2010-05-04 RU RU2011145434/10A patent/RU2539034C2/ru not_active IP Right Cessation
- 2010-05-04 JP JP2012509009A patent/JP2012530047A/ja active Pending
- 2010-05-04 CA CA2760755A patent/CA2760755A1/en not_active Abandoned
- 2010-05-04 EP EP10717145A patent/EP2427495A1/en not_active Ceased
- 2010-05-04 US US13/318,149 patent/US20120116059A1/en not_active Abandoned
- 2010-05-04 KR KR1020147009468A patent/KR20140064943A/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| RU2539034C2 (ru) | 2015-01-10 |
| KR20120011883A (ko) | 2012-02-08 |
| AU2010244525A1 (en) | 2011-11-10 |
| KR20140064943A (ko) | 2014-05-28 |
| CA2760755A1 (en) | 2010-11-11 |
| RU2011145434A (ru) | 2013-06-10 |
| US20120116059A1 (en) | 2012-05-10 |
| WO2010128035A1 (en) | 2010-11-11 |
| EP2427495A1 (en) | 2012-03-14 |
| CN102439039A (zh) | 2012-05-02 |
| AU2010244525B2 (en) | 2013-03-28 |
| JP2012530047A (ja) | 2012-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2515984A4 (en) | INTERFACE | |
| DK2414015T3 (da) | Laryngoskopsystem | |
| DK2411442T4 (da) | Umættet polyesterresin | |
| DE112010004215A5 (de) | Hydrostataktor | |
| DE112010002949A5 (de) | Kupplungstastpunkte | |
| EP2469625A4 (en) | OMNIBUS BAR | |
| EP2445547A4 (en) | CATHETERISM SYSTEM | |
| EP2491340A4 (en) | TELEMETRY PHOTOGRAPHIC APPARATUS | |
| EP2440486A4 (en) | CABLE RETRACTION SYSTEM | |
| EP2509489A4 (en) | SPRINKLER FOR EARLY HEEL REMOVAL | |
| DK2430035T3 (da) | Uracylspipooxetannukleosider | |
| BRPI1008827A2 (pt) | deisobutenizador | |
| BR112012000657A2 (pt) | novos azabicilohexanos | |
| BRPI1014968A2 (pt) | subalargador | |
| DE112010002728A5 (de) | Turboinhalator | |
| EP2499707A4 (en) | INTERFACE | |
| DE112010004249A5 (de) | Spindelaktor | |
| DE112009005323A5 (de) | Hebelarmprüfmaschine | |
| EP2415046C0 (en) | SHOULDER BRACKET | |
| DE112009005462T8 (de) | Lenkungsssteuervorrichtung | |
| EP2446176A4 (en) | CYLINDER SEAL | |
| EP2402744A4 (en) | CARBURATION DETECTION METHOD | |
| BR112012004964A2 (pt) | girocóptero | |
| BRPI1008070A2 (pt) | tricianoboratos | |
| EP2409976A4 (en) | GLYCINE TRANSPORTER INHIBITOR |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2506 DE 15-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |